LINC00511: A promising drug target and biomarker for cancer (G400619)

Target Name: LINC00511

NCBI ID: G400619

LINC00511

Other Name(s): onco-lncRNA-12 | long intergenic non-protein coding RNA 511 | LCAL5 | Long intergenic non-protein coding RNA 511

LINC00511: A promising drug target and biomarker for cancer

Introduction

LINC00511 is a non-coding RNA (ncRNA) that has been identified as an oncogenic gene in various cancer types. This RNA has been shown to play a significant role in the development and progression of cancer. It is a known fact that LINC00511 has high expression levels in various cancer tissues, including breast, ovarian, and colorectal cancer. The identification of LINC00511 as an oncogenic gene has led to a growing interest in it as a potential drug target or biomarker.

Drug Target

LINC00511 has been shown to be involved in the regulation of various cellular processes, including cell growth, apoptosis, and angiogenesis. It has been shown to promote the growth and survival of cancer cells, and it has been shown to contribute to the development of cancer . LINC00511 has also been shown to play a role in the regulation of the blood-brain barrier, which is a barrier that separates the brain from the blood and is responsible for controlling the flow of nutrients and drugs into the brain.

Studies have shown that LINC00511 can be targeted by small molecules, including inhibitors that can inhibit its expression or activity. These small molecules have been shown to have a negative impact on the growth and survival of cancer cells. LINC00511 has also been shown to interact with various proteins, including the protein kinase A3 (PPKG1). PPKG1 is a known protein that plays a role in the regulation of cell growth and apoptosis, and it is a potential target for LINC00511 inhibitors.

Biomarker

LINC00511 has also been shown to be a potential biomarker for cancer. Its high expression levels in cancer tissues make it a promising target for diagnostic tools. Studies have shown that LINC00511 has been shown to be upregulated in various cancer types, including breast, ovarian, and colorectal cancer. This suggests that LINC00511 may be a useful biomarker for these cancers.

Another study has shown that LINC00511 has been shown to be downregulated in the serum of cancer patients. This suggests that LINC00511 may be a potential biomarker for cancer recurrence.

Conclusion

In conclusion, LINC00511 is a promising drug target and biomarker for cancer. Its oncogenic properties and interaction with PPKG1 make it a potential target for small molecules that can inhibit its expression or activity. Further studies are needed to confirm its potential as a drug target or biomarker for cancer.

Protein Name: Long Intergenic Non-protein Coding RNA 511

The "LINC00511 Target / Biomarker Review Report" is a customizable review of hundreds up to thousends of related scientific research literature by AI technology, covering specific information about LINC00511 comprehensively, including but not limited to:
•   general information;
•   protein structure and compound binding;
•   protein biological mechanisms;
•   its importance;
•   the target screening and validation;
•   expression level;
•   disease relevance;
•   drug resistance;
•   related combination drugs;
•   pharmacochemistry experiments;
•   related patent analysis;
•   advantages and risks of development, etc.
The report is helpful for project application, drug molecule design, research progress updates, publication of research papers, patent applications, etc. If you are interested to get a full version of this report, please feel free to contact us at BD@silexon.ai

More Common Targets